Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Adaptive Biotechnologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$33.83|
|52 Week High||US$29.74|
|52 Week Low||US$71.25|
|1 Month Change||-7.29%|
|3 Month Change||-9.06%|
|1 Year Change||-33.95%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-16.06%|
Recent News & Updates
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ADPT||US Life Sciences||US Market|
Return vs Industry: ADPT underperformed the US Life Sciences industry which returned 36.1% over the past year.
Return vs Market: ADPT underperformed the US Market which returned 33.4% over the past year.
Stable Share Price: ADPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ADPT's weekly volatility (7%) has been stable over the past year.
About the Company
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines.
Adaptive Biotechnologies Fundamentals Summary
|ADPT fundamental statistics|
Is ADPT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADPT income statement (TTM)|
|Cost of Revenue||US$170.75m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 03, 2021
|Earnings per share (EPS)||-1.22|
|Net Profit Margin||-128.33%|
How did ADPT perform over the long term?See historical performance and comparison
Is Adaptive Biotechnologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ADPT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ADPT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ADPT is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: ADPT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADPT is overvalued based on its PB Ratio (6.9x) compared to the US Life Sciences industry average (6.5x).
How is Adaptive Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADPT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADPT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADPT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADPT's revenue (25.7% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ADPT's revenue (25.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ADPT is forecast to be unprofitable in 3 years.
How has Adaptive Biotechnologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADPT is currently unprofitable.
Growing Profit Margin: ADPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADPT is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.
Accelerating Growth: Unable to compare ADPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADPT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (46.6%).
Return on Equity
High ROE: ADPT has a negative Return on Equity (-24.7%), as it is currently unprofitable.
How is Adaptive Biotechnologies's financial position?
Financial Position Analysis
Short Term Liabilities: ADPT's short term assets ($643.7M) exceed its short term liabilities ($116.6M).
Long Term Liabilities: ADPT's short term assets ($643.7M) exceed its long term liabilities ($223.4M).
Debt to Equity History and Analysis
Debt Level: ADPT is debt free.
Reducing Debt: ADPT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ADPT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 64.3% each year
What is Adaptive Biotechnologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chad Robins (47 yo)
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
CEO Compensation Analysis
Compensation vs Market: Chad's total compensation ($USD7.13M) is above average for companies of similar size in the US market ($USD5.21M).
Compensation vs Earnings: Chad's compensation has increased whilst the company is unprofitable.
Experienced Management: ADPT's management team is considered experienced (3.7 years average tenure).
Experienced Board: ADPT's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ADPT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.7%.
Adaptive Biotechnologies Corporation's employee growth, exchange listings and data sources
- Name: Adaptive Biotechnologies Corporation
- Ticker: ADPT
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.762b
- Shares outstanding: 140.77m
- Website: https://www.adaptivebiotech.com
Number of Employees
- Adaptive Biotechnologies Corporation
- 1165 Eastlake Avenue East
- Suite 200
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:40|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.